Canadian study shows the estimated annual cost of inappropriate B12 prescribing was $45.6 million, assuming a 64% inappropriate prescription rate. Only 1.7% of prescribed intramuscular B12 demonstrated any deficiency with a malabsorptive indication https://t.co/yYW9oDjjPZ